<?xml version="1.0" encoding="UTF-8" standalone="no"?><?xml-stylesheet type="text/css" href="uslm.css"?><pLaw xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm https://www.govinfo.gov/schemas/xml/uslm/uslm-2.0.17.xsd">

<?I97 ??>
<?I50 PUBLIC LAW 117–350—JAN. 5, 2023?>


<?I97 136 STAT. ?>
<?I98 136 STAT. ?>
<?I99 136 STAT. ?>
<?I50 PUBLIC LAW 117–350—JAN. 5, 2023?>
<?I51 PUBLIC LAW 117–350—JAN. 5, 2023?>
<?I52 PUBLIC LAW 117–350—JAN. 5, 2023?>


<!--Disclaimer: Legislative measures that include compacts or other non-standard data structures will require additional modeling and may contain inconsistencies in the converted USLM XML.-->
<meta><dc:title>Public Law 117–350: To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.</dc:title>
<dc:type>Public Law</dc:type><docNumber>350</docNumber>
<citableAs>Public Law 117–350</citableAs><citableAs>136 Stat. 6262</citableAs>
<approvedDate>2023-01-05</approvedDate>
<dc:date>2023-01-05</dc:date>
<dc:publisher>United States Government Publishing Office</dc:publisher><dc:creator>National Archives and Records Administration</dc:creator><dc:creator>Office of the Federal Register</dc:creator><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<processedBy>GPO Locator to USLM Converter 4.15.31;Stage2.20250702</processedBy><processedDate>2026-01-02</processedDate>
<congress>117</congress><publicPrivate>public</publicPrivate>
</meta>
<preface><page display="no">?6261</page><note role="coverPage"><centerRunningHead>PUBLIC LAW 117–350—JAN. 5, 2023</centerRunningHead>
<coverTitle>CHILDHOOD CANCER SURVIVORSHIP, TREATMENT, ACCESS, AND RESEARCH REAUTHORIZATION ACT OF 2022</coverTitle>
</note>
<page identifier="/us/stat/136/6262">136 STAT. 6262</page>
<dc:type>Public Law</dc:type><docNumber>117–350</docNumber>
<congress value="117">117th Congress</congress>
</preface>
<main>
<longTitle>
<docTitle class="centered fontsize12" style="-uslm-lc:I658005">An Act</docTitle>
<officialTitle class="indentUp0 firstIndent1 fontsize8" style="-uslm-lc:I658011">To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.<sidenote><p class="centered fontsize8" id="x62f700b0-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658076"><approvedDate date="2023-01-05">Jan. 5, 2023</approvedDate></p><p class="centered fontsize8" id="x62f700b1-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658076">[<ref href="/us/bill/117/s/4120">S. 4120</ref>]<?GPOvSpace 08?></p></sidenote></officialTitle>
</longTitle>
<enactingFormula style="-uslm-lc:I658120"><i>  Be it enacted by the Senate and House of Representa­tives of the United States of America in Congress assembled,</i></enactingFormula><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62f700b2-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658180">Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022.</p></sidenote>
<section id="d47424e98" identifier="/us/pl/117/350/s1" style="-uslm-lc:I658146"><num class="bold" value="1">SECTION 1. </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62f700b3-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658180"><ref href="/us/usc/t42/s201">42 USC 201 note</ref>.</p></sidenote><heading>SHORT TITLE.</heading><content style="-uslm-lc:I658120">  This Act may be cited as the “<shortTitle role="act">Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022</shortTitle>” or the “<shortTitle role="act">Childhood Cancer STAR Reauthorization Act</shortTitle>”.</content></section>
<section id="d47424e116" identifier="/us/pl/117/350/s2" style="-uslm-lc:I658141"><num class="fontsize12" value="2">SEC. 2. </num><heading>REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT.</heading><subsection class="firstIndent0 fontsize10" id="y62f7eb14-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/a" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10"><inline class="smallCaps">Children’s Cancer Biorepositories</inline>.—</heading><chapeau>Section 417E of the Public Health Service Act (<ref href="/us/usc/t42/s285a–11">42 U.S.C. 285a–11</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="y62f7eb15-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/a/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><chapeau>in subsection (a)—</chapeau><subparagraph class="fontsize10" id="y62f7eb16-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/a/1/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>in paragraph (2)(A), by <amendingAction type="insert">inserting</amendingAction> before the period at the end of the second sentence the following: “<quotedText>, such as collected samples of both solid tumor cancer and paired samples</quotedText>”;</content></subparagraph>
<subparagraph class="fontsize10" id="y62f7eb17-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/a/1/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>in paragraph (9), by <amendingAction type="delete">striking</amendingAction> “<quotedText>Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022</quotedText>”;</content></subparagraph>
<subparagraph class="fontsize10" id="y62f7eb18-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/a/1/C" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><content>by <amendingAction type="redesignate">redesignating</amendingAction> paragraph (10) as paragraph (11); and</content></subparagraph>
<subparagraph class="fontsize10" id="y62f7eb19-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/a/1/D" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">(D) </num><content>by <amendingAction type="insert">inserting</amendingAction> after paragraph (9) the following:<quotedContent><paragraph class="indentDown1 fontsize10" id="y62f8122a-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="10">“(10) </num><heading class="fontsize10"><inline class="smallCaps">Report on researcher access to children’s cancer biorepository samples</inline>.—</heading><chapeau>Not later than 2 years after the date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022, the Director of NIH shall—</chapeau><subparagraph class="fontsize10" id="y62f8122b-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62f8122c-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658180">Review.</p></sidenote><content>conduct a review of the procedures established under paragraph (2)(C) and other policies or procedures related to researcher access to such biospecimens to identify any opportunities to reduce administrative burden, consistent with paragraph (2)(D), in a manner that protects personal privacy to the extent required by applicable Federal and State privacy law, at a minimum; and</content></subparagraph>
<subparagraph class="fontsize10" id="y62f8122d-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the findings of the review under subparagraph (A) and whether the Director of NIH plans to make any changes to the policies or procedures considered in such review, based on such findings.”</content></subparagraph>
</paragraph>
</quotedContent>; and<page identifier="/us/stat/136/6263">136 STAT. 6263</page></content></subparagraph>
</paragraph>
<paragraph class="fontsize10" id="y62f8122e-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/a/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>in subsection (d), by <amendingAction type="delete">striking</amendingAction> “<quotedText>2019 through 2023</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>2024 through 2028</quotedText>”.</content></paragraph>
</subsection>
<subsection class="firstIndent0 fontsize10" id="y62f8122f-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><heading class="fontsize10"><inline class="smallCaps">Cancer Survivorship Programs</inline>.—</heading><chapeau>Section 201 of the Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018 (<ref href="/us/pl/115/180">Public Law 115–180</ref>)<sidenote><p class="leftAlign firstIndent0 fontsize8" id="x62f81230-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658180"><ref href="/us/usc/t42/s285a–11a">42 USC 285a–11a note</ref>.</p></sidenote> <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="y62f81231-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><chapeau>in subsection (a)—</chapeau><subparagraph class="fontsize10" id="y62f81232-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>in the subsection heading, by <amendingAction type="delete">striking</amendingAction> “<quotedText><headingText class="smallCaps">Pilot Programs to Explore</headingText></quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText><headingText class="smallCaps">Research to Evaluate</headingText></quotedText>”</content></subparagraph>
<subparagraph class="fontsize10" id="y62f81233-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><chapeau>in paragraph (1)—</chapeau><clause class="fontsize10" id="y62f81234-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/B/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>may make awards to eligible entities to establish pilot programs</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>shall, as appropriate, make awards to eligible entities to conduct or support research</quotedText>”;</content></clause>
<clause class="fontsize10" id="y62f81235-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/B/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>model systems</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>approaches</quotedText>”;</content></clause>
<clause class="fontsize10" id="y62f81236-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/B/iii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">(iii) </num><content>by <amendingAction type="insert">inserting</amendingAction> “<quotedText>and adolescent</quotedText>” after “<quotedText>childhood</quotedText>”; and</content></clause>
<clause class="fontsize10" id="y62f81237-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/B/iv" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iv">(iv) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>evaluation of models for</quotedText>”;</content></clause>
</subparagraph>
<subparagraph class="fontsize10" id="y62f81238-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/C" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><chapeau>in paragraph (2)—</chapeau><clause class="fontsize10" id="y62f81239-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/C/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><content>in subparagraph (A), in the matter preceding clause (i), by <amendingAction type="insert">inserting</amendingAction> “<quotedText>within the existing peer review process,</quotedText>” after “<quotedText>practicable,</quotedText>”; and</content></clause>
<clause class="fontsize10" id="y62f8123a-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/C/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>in subparagraph (B)(v), by <amendingAction type="delete">striking</amendingAction> “<quotedText>in treating survivors of childhood cancers</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>in carrying out the activities described in paragraph (1)</quotedText>”; and</content></clause>
</subparagraph>
<subparagraph class="fontsize10" id="y62f8123b-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/1/D" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">(D) </num><content>in paragraph (3)(B)(v), by <amendingAction type="delete">striking</amendingAction> “<quotedText>design of systems for the effective transfer of treatment information and care summaries from cancer care providers to other health care providers</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>design tools to support the secure electronic transfer of treatment information and care summaries between health care providers or, as applicable and appropriate, longitudinal childhood cancer survivorship cohorts</quotedText>”; and</content></subparagraph>
</paragraph>
<paragraph class="fontsize10" id="y62f8123c-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><chapeau>in subsection (b)—</chapeau><subparagraph class="fontsize10" id="y62f8123d-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/2/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>in each of paragraphs (1) and (2), by <amendingAction type="delete">striking</amendingAction> “<quotedText>date of enactment of this Act</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022</quotedText>”; and</content></subparagraph>
<subparagraph class="fontsize10" id="y62f8123e-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/2/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><chapeau>in paragraph (1)—</chapeau><clause class="fontsize10" id="y62f8123f-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/2/B/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><content>by <amendingAction type="delete">striking</amendingAction> subparagraphs (A) and (C);</content></clause>
<clause class="fontsize10" id="y62f81240-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/2/B/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>by <amendingAction type="redesignate">redesignating</amendingAction> subparagraph (B) as subparagraph (A); and</content></clause>
<clause class="fontsize10" id="y62f81241-e814-11f0-a1e4-69761a48a15a" identifier="/us/pl/117/350/s2/b/2/B/iii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">(iii) </num><content>by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subparagraph class="indentDown1 fontsize10" id="y62f81242-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>recommendations for enhancing or promoting activities of the Department of Health and Human Services related to workforce development for health care providers<page identifier="/us/stat/136/6264">136 STAT. 6264</page>
 who provide psychosocial care to pediatric cancer patients and survivors.”</content></subparagraph>
</quotedContent>.</content></clause>
</subparagraph>
</paragraph>
</subsection>
</section>
<action>
<actionDescription style="-uslm-lc:I658030">Approved</actionDescription> <date date="2023-01-05">January 5, 2023</date>.</action>
</main>
<legislativeHistory>
<heading style="-uslm-lc:I658031"><inline class="underline">LEGISLATIVE HISTORY</inline>—<ref href="/us/bill/117/s/4120">S. 4120</ref>:</heading>
<note>
<heading style="-uslm-lc:I658032">CONGRESSIONAL RECORD, Vol. 168 (2022):</heading>
<p class="indentUp4 firstIndent-1" id="x62f81243-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658035">Dec. 20, considered and passed Senate.</p><p class="indentUp4 firstIndent-1" id="x62f81244-e814-11f0-a1e4-69761a48a15a" style="-uslm-lc:I658035">Dec. 22, considered and passed House.</p></note>
</legislativeHistory>
<endMarker>○</endMarker>
</pLaw>